• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $UPXI

    Upexi Inc.

    Subscribe to $UPXI
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    IPO Year: 2021

    Exchange: NASDAQ

    Recent Analyst Ratings for Upexi Inc.

    DatePrice TargetRatingAnalyst
    8/4/2025$15.00Buy
    Alliance Global Partners
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    See more ratings

    Upexi Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Upexi, Inc. with a new price target

    Alliance Global Partners initiated coverage of Upexi, Inc. with a rating of Buy and set a new price target of $15.00

    8/4/25 8:09:26 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

    6/16/25 7:42:40 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    CSO Rudick Brian Benjamin was granted 400,000 shares, increasing direct ownership by 91% to 838,597 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:09:34 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Williams Thomas Charles was granted 100,000 shares (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:03:45 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan bought $799,998 worth of shares (161,943 units at $4.94) and was granted 1,200,000 shares, increasing direct ownership by 154% to 2,246,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:03:08 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Norstrud Andrew James was granted 250,000 shares, increasing direct ownership by 157% to 409,138 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:02:25 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    New insider Rudick Brian Benjamin claimed ownership of 438,597 shares (SEC Form 3)

    3 - UPEXI, INC. (0001775194) (Issuer)

    6/3/25 6:04:17 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    4/25/25 4:01:36 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Director Williams Thomas Charles

    4 - UPEXI, INC. (0001775194) (Issuer)

    4/25/25 4:01:45 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    4/25/25 4:01:26 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan bought $799,998 worth of shares (161,943 units at $4.94) and was granted 1,200,000 shares, increasing direct ownership by 154% to 2,246,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:03:08 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    4/25/25 4:01:36 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    4/25/25 4:01:26 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Salkind Gene bought $550,002 worth of shares (241,229 units at $2.28), increasing direct ownership by 195% to 365,127 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    4/25/25 4:01:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Marshall Allan bought $44,739 worth of shares (77,773 units at $0.58), increasing direct ownership by 3% to 2,939,654 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    3/18/24 4:55:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Marshall Allan bought $72,109 worth of shares (103,013 units at $0.70), increasing direct ownership by 4% to 2,861,881 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    3/6/24 3:04:50 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Marshall Allan bought $12,340 worth of shares (12,916 units at $0.96), increasing direct ownership by 0.47% to 2,767,249 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/20/23 1:37:18 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Marshall Allan bought $84,952 worth of shares (90,001 units at $0.94), increasing direct ownership by 3% to 2,754,333 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/7/23 2:42:38 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. Leadership Updates

    Live Leadership Updates

    View All

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    5/31/23 7:05:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:37:37 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    SC 13G/A - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:36:56 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    SC 13G/A - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:36:22 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. Financials

    Live finance-specific insights

    View All

    Upexi Purchases 83,000 SOL, Grows Treasury to 1.9 Million SOL Worth $381 Million

    TAMPA, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the acquisition of 83,000 SOL for $16.7 million, or $201.34 per SOL. The purchase brings the Company's holdings to 1.9 million SOL worth over $381 million using the $200.60 spot price of Solana as of 5:00 pm ET yesterday. Allan Marshall, Chief Executive Officer of Upexi, remarked, "The U.S. continues to make progress around digital asset legislation, which has the potential to usher in mass adoption of blockchain technology.

    7/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Grows Treasury to 1.819 Million SOL Worth $331 Million with a $58 Million Unrealized Gain in Under Three Months

    Upexi purchased an additional 100,000 SOL, and anticipates it may generate up to approximately $26 million in annual staking revenue based on current SOL holdingsCompany releases adjusted metrics for enhanced transparency and analysis TAMPA, Fla., July 21, 2025 (GLOBE NEWSWIRE) --  Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the acquisition of 100,000 SOL, bringing its treasury holdings to 1,818,809 SOL worth $331 million. The recent purchase follows the successful closing of a roughly $200 million equity and c

    7/21/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Regains Compliance with NASDAQ

    Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

    12/23/24 9:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Reports Fiscal Second Quarter 2024 Financial Results

    TAMPA, FL / ACCESSWIRE / February 14, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today reported its financial results for the fiscal second quarter 2024 ending December 31, 2023."During the quarter we continued to focus on optimizing and streamlining our operations, investing in our higher margin Brand Products and generating positive Adjusted EBITDA. While revenue for the most recent fiscal second quarter decreased sequentially, the operating measures we took allowed us to increase gross profit margins to 38%, as compared to the prior fiscal first quarter of 31.8%. We also generated pos

    2/14/24 4:05:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Host Fiscal 2024 Second Quarter Financial Results Conference Call on February 14th at 4:30 PM ET

    TAMPA, FL / ACCESSWIRE / February 12, 2024 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Wednesday, February 14, 2024 at 4:30 p.m. ET, to discuss its financial results for the fiscal 2024 second quarter and provide a business update.Financial Results Conference CallEvent:Fiscal 2024 Second Quarter Financial Results Conference CallDate:Wednesday, February 14, 2024Time:4:30 p.m. Eastern TimeLive Call:1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)Webcast:https://ir.upexi.com/news-events/ir-calendarFor those unable to join the confe

    2/12/24 9:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Revenue Increases 144% Year-Over-Year and 53.5% Sequentially to $27.3 Million for Fiscal First Quarter 2024

    TAMPA, FL / ACCESSWIRE / November 20, 2023 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today announced its financial results for the fiscal first quarter 2024 ending September 30, 2023."Revenue for our fiscal first quarter 2024 grew 144% year-over-year and 53.5% sequentially driven by growth in both branded products and re-commerce," commented CEO of Upexi, Allan Marshall. "While our cost cutting measures are now beginning to yield material year-over-year decreases in operating expenses as a percentage of revenue, we have also continued to invest significantly in the future growth of our brand

    11/20/23 4:05:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Preannounces Revenue of $27.3 Million for Fiscal 2024 First Quarter and Reschedules Financial Results Conference Call for November 20th at 4:30 PM ET

    TAMPA, FL / ACCESSWIRE / November 14, 2023 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced preliminary and unaudited financial results for the fiscal 2024 first quarter ended September 30, 2023.Based on a preliminary and unaudited review, the Company anticipates:Revenue of approximately $27.3 million, an increase of 136% year-over-year and 53.2% sequentially, and above the previously issue revenue guidance range of $26 million to $27 million.Adjusted EBITDA of approximately $700,000 as compared to an Adjusted EBITDA loss of approximately $525,000, approximately a $1.2 million improv

    11/14/23 9:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Host Fiscal 2024 First Quarter Financial Results Conference Call on November 14th at 4:30 PM ET

    TAMPA, FL / ACCESSWIRE / November 3, 2023 / Upexi Inc. (NASDAQ:PXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Tuesday, November 14, 2023 at 4:30 p.m. ET, to discuss its financial results for the first quarter of fiscal 2024 and provide a business update.Financial Results Conference CallEvent:Fiscal 2024 First Quarter Financial Results Conference CallDate:Tuesday, November 14, 2023Time:4:30 p.m. Eastern TimeLive Call:1-877-300-8521 (U.S. Toll-Free) or 1-412-317-6026 (International)Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1641098&tp_key=e91f34a943For those una

    11/3/23 8:30:00 AM ET
    $PXI
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Fiscal 2023 Revenue Increases 250% Year-Over-Year to $80.7 Million and Provides Revenue Guidance Range for Fiscal 2023 First Quarter

    Management provides revenue guidance range for fiscal 2023 first quarter of $26 million to $27 millionTAMPA, FL / ACCESSWIRE / October 2, 2023 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today announced its financial results for the fiscal year ending June 30, 2023."Revenue growth year-over-year was predominately driven by the performance of our leading brands, VitaMetica, Lucky Tail and Tytan Tiles, as well as our re-commerce business. Even as we continue to integrate the operations of our acquisitions and reduced non-acquisition operating expenses by $1.9 million, we were able to report $1.2

    10/2/23 4:01:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Host Fiscal 2023 Full Year Financial Results Conference Call on October 2nd at 4:30 PM ET

    CLEARWATER, FL / ACCESSWIRE / September 28, 2023 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Monday, October 2, 2023 at 4:30 p.m. ET, to discuss its financial results for the fiscal 2023 full year and provide a business update.Financial Results Conference CallEvent:Fiscal 2023 Full Year Financial Results Conference CallDate:Monday, October 2, 2023Time:4:30 p.m. Eastern TimeLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1634526&tp_key=7536fca2faFor those unable to jo

    9/28/23 4:15:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Surpasses 2 Million SOL in its Treasury

    TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today released its periodic update. "July was a game-changing month for Upexi, particularly with respect to accretive capital raises and a resulting drastic increase in our Solana treasury," stated Allan Marshall, Upexi's Chief Executive Officer. "During the month, we raised over $200 million and grew our Solana holdings by over 172% to 2 million SOL. And we continued to generate additional value fo

    8/5/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference on August 12th-14th

    TAMPA, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced that management will participate in a fireside chat moderated by Joseph Vafi, Managing Director of Equity Research at Canaccord Genuity LLC, on Wednesday, August 13th at 1:30 p.m. ET at the Canaccord Genuity 45th Annual Growth Conference taking place at the InterContinental in Boston, MA. Presentation details, including a link to the live webcast, can be found below. Canaccord Genuity Conference:Dates: August 12-14, 2025Loc

    7/30/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. Announces $500 Million Equity Line Agreement with A.G.P. to Accelerate the Growth of its Solana Treasury Strategy

    TAMPA, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced it has entered into an equity line agreement with A.G.P./Alliance Global Partners enabling Upexi to sell up to $500 million of the Company's common stock at the Company's sole discretion, subject to certain restrictions and closing conditions. Any proceeds from the equity line, which included no commitment fee, will be used for general corporate purposes and to further the Company's Solana treasury strategy. Allan Marshall,

    7/28/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Purchases 83,000 SOL, Grows Treasury to 1.9 Million SOL Worth $381 Million

    TAMPA, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the acquisition of 83,000 SOL for $16.7 million, or $201.34 per SOL. The purchase brings the Company's holdings to 1.9 million SOL worth over $381 million using the $200.60 spot price of Solana as of 5:00 pm ET yesterday. Allan Marshall, Chief Executive Officer of Upexi, remarked, "The U.S. continues to make progress around digital asset legislation, which has the potential to usher in mass adoption of blockchain technology.

    7/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Grows Treasury to 1.819 Million SOL Worth $331 Million with a $58 Million Unrealized Gain in Under Three Months

    Upexi purchased an additional 100,000 SOL, and anticipates it may generate up to approximately $26 million in annual staking revenue based on current SOL holdingsCompany releases adjusted metrics for enhanced transparency and analysis TAMPA, Fla., July 21, 2025 (GLOBE NEWSWIRE) --  Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the acquisition of 100,000 SOL, bringing its treasury holdings to 1,818,809 SOL worth $331 million. The recent purchase follows the successful closing of a roughly $200 million equity and c

    7/21/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Announces Closing of Approximately $150 Million Private Placement of Convertible Notes as Part of Previously Announced $200 Million Concurrent Offering

    TAMPA, Fla., July 17, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the closing of a private placement convertible note offering, with such convertible notes issued in exchange for locked and spot Solana ("SOL"), with an aggregate original principal amount of approximate $150 million (the "Note Offering") with certain institutional investors and qualified purchasers. The closing of the Note Offering alongside the previously disclosed $50 million private placement of common stock (the "Equity

    7/17/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Announces Closing of $50 Million Private Placement Equity Offering

    TAMPA, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the closing of a private placement equity offering of 12,457,186 shares of common stock (the "Equity Offering") with certain accredited investors, qualified purchasers and institutional investors, as well as Allan Marshall, the Company's Chief Executive Officer and Gene Salkind, Director, for the purchase and sale of 12,457,186 shares of common stock at a price of $4.00 per share (and at a price of $4.94 per share for manageme

    7/15/25 8:36:44 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. Announces Pricing of $200 Million Concurrent Private Placement of Common Stock and Convertible Notes both Priced above the At-the-Market Price under Nasdaq Rules

    TAMPA, Fla., July 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced that it has entered into securities purchase agreements with certain accredited investors, qualified purchasers and institutional investors, as well as with Allan Marshall, the Company's Chief Executive Officer, for the purchase and sale of 12,457,186 shares of common stock (or common stock equivalents in lieu thereof) at a price of $4.00 per share (and at a price of $4.94 per share for management's participation) for aggregat

    7/11/25 8:30:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. June 2025 Monthly Update

    TAMPA, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today released its June 2025 monthly update. "June was a particularly active and successful month," stated Upexi CEO Allan Marshall. "We increased our SOL balance during June by 8%, demonstrating continued growth while also continuing to earn an 8% staking yield. And we delivered on key initiatives, gaining listed options on Nasdaq, announcing our intention to tokenize our equity via Superstate, and joining Webull's Corporate Connect Service platform. Looking ahead,

    7/8/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. SEC Filings

    View All

    Upexi Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - UPEXI, INC. (0001775194) (Filer)

    8/20/25 5:00:44 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    8/15/25 5:00:34 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-1 filed by Upexi Inc.

    S-1 - UPEXI, INC. (0001775194) (Filer)

    8/11/25 7:30:24 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    8/8/25 5:01:01 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEF 14A filed by Upexi Inc.

    DEF 14A - UPEXI, INC. (0001775194) (Filer)

    8/8/25 12:27:11 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form S-1/A filed by Upexi Inc.

    S-1/A - UPEXI, INC. (0001775194) (Filer)

    8/8/25 6:18:39 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Upexi Inc.

    SCHEDULE 13G/A - UPEXI, INC. (0001775194) (Subject)

    8/5/25 5:35:39 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    8/1/25 5:01:40 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form PRE 14A filed by Upexi Inc.

    PRE 14A - UPEXI, INC. (0001775194) (Filer)

    7/29/25 5:00:11 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form D filed by Upexi Inc.

    D - UPEXI, INC. (0001775194) (Filer)

    7/29/25 2:25:29 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care